Literature DB >> 6376234

Factors governing the human immune response to injected insulin.

W G Reeves, D Barr, C A Douglas, K Gelsthorpe, I Hanning, A Skene, L Wells, R M Wilson, R B Tattersall.   

Abstract

Seventy-nine patients were observed prospectively during their initial period of treatment with conventional bovine insulins. Insulin antibody levels 6 months after starting insulin therapy did not correlate with age, gender or beta cell function at onset of treatment. Patients who required soluble insulin in addition to isophane insulin developed higher levels of insulin antibody. Patients bearing the HLA-B8, DR3 and C4AQO alleles had lower levels of insulin antibody, whereas those bearing DR7 produced significantly higher levels. Other alleles at the C4A, C4B, C2, factor B or Gm loci did not appear to have a significant effect on insulin antibody production. The hyporesponsiveness of B8/DR3/ C4AQO -positive individuals probably reflects a non-specific abnormality of immunity whereas the enhanced responsiveness of those positive for DR7 suggests the presence of a specific immune response gene for insulin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376234     DOI: 10.1007/bf00283648

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

1.  Macrophage or T cell - that is the question.

Authors:  Z A Nagy; J Klein
Journal:  Immunol Today       Date:  1981-12

2.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

3.  The immune response to insulin in man. Interaction of HLA alloantigens and the development of the immune response.

Authors:  C R Kahn; D Mann; A S Rosenthal; J A Galloway; A H Johnson; N Mendell
Journal:  Diabetes       Date:  1982-08       Impact factor: 9.461

4.  Disease associations with complotypes, supratypes and haplotypes.

Authors:  R L Dawkins; F T Christiansen; P H Kay; M Garlepp; J McCluskey; P N Hollingsworth; P J Zilko
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

5.  Statement on the nomenclature of human C4 allotypes.

Authors:  G Mauff; C A Alper; Z Awdeh; J R Batchelor; J Bertrams; G Bruun-Petersen; R L Dawkins; P Démant; J Edwards; H Grosse-Wilde; G Hauptmann; P Klouda; L Lamm; E Mollenhauer; C Nerl; B Olaisen; G O'Neill; C Rittner; M H Roos; V Skanes; P Teisberg; L Wells
Journal:  Immunobiology       Date:  1983-03       Impact factor: 3.144

6.  Immunology. Molecular biology of the major histocompatibility complex.

Authors:  J Lee; J Trowsdale
Journal:  Nature       Date:  1983 Jul 21-27       Impact factor: 49.962

7.  The immunogenicity of insulin preparation. Antibody levels before and after transfer to highly purified porcine insulin.

Authors:  L G Heding; Y Larsson; J Ludvigsson
Journal:  Diabetologia       Date:  1980       Impact factor: 10.122

8.  Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects.

Authors:  T J Lawley; R P Hall; A S Fauci; S I Katz; M I Hamburger; M M Frank
Journal:  N Engl J Med       Date:  1981-01-22       Impact factor: 91.245

9.  C-peptide antibodies induced by bovine insulin therapy.

Authors:  W G Reeves; C A Douglas
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

10.  Insulin antibodies induced by bovine insulin therapy.

Authors:  W G Reeves; U Kelly
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

View more
  6 in total

1.  Insulin binding substances, autoimmunity and type I diabetes in Kuwaiti patients and their kindred.

Authors:  E R Richens; A Shaltout; G M Bahr; N Abdella; A K Jayyab; M Al-Saffar; K Behbehani
Journal:  Acta Diabetol Lat       Date:  1989 Apr-Jun

2.  Phenotypes of the heavy chains of immunoglobulins in patients with diabetic microangiopathy: evidence for an immunogenetic predisposition.

Authors:  C Mijovic; J A Fletcher; A R Bradwell; A H Barnett
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

3.  HLA phenotype and insulin antibody production.

Authors:  W G Reeves; K Gelsthorpe; P Van der Minne; R Torensma; R B Tattersall
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

4.  Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus.

Authors:  K Zuppinger; C Aebi; S Fankhauser; G Herz; R P Zurbrügg; K Schopfer; T M Neri
Journal:  Diabetologia       Date:  1987-12       Impact factor: 10.122

5.  Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins.

Authors:  R M Wilson; C A Douglas; R B Tattersall; W G Reeves
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

6.  Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices.

Authors:  N Jeandidier; S Boivin; R Sapin; F Rosart-Ortega; B Uring-Lambert; P Réville; M Pinget
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.